Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog

Res Vet Sci. 1994 Mar;56(2):144-50. doi: 10.1016/0034-5288(94)90096-5.

Abstract

The pharmacokinetic profile of antimony in dogs was defined by administering it intravenously, intramuscularly and subcutaneously as N-methylglucamine antimoniate at a dose of about 25.65 mg of antimony kg-1 bodyweight. The results showed a different half-life for the three routes of administration: 20.5, 42.1 and 121.6 minutes for the intravenous, intramuscular and subcutaneous routes, respectively; peak time values (Tmax) were also different for the intramuscular (90 to 120 minutes) and subcutaneous (210 to 240 minutes) injection. The apparent bioavailability of antimony was > 100 per cent for the intramuscular and 100 per cent for the subcutaneous routes. The data obtained showed a relevant difference in the behaviour of the drug in the dog in comparison to that in humans.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimony / blood
  • Antimony / pharmacokinetics*
  • Antimony / urine
  • Biological Availability
  • Dogs
  • Female
  • Half-Life
  • Injections, Intramuscular / veterinary
  • Injections, Intravenous / veterinary
  • Injections, Subcutaneous / veterinary
  • Male
  • Meglumine / administration & dosage
  • Meglumine / blood
  • Meglumine / pharmacokinetics*
  • Meglumine / urine
  • Meglumine Antimoniate
  • Metabolic Clearance Rate
  • Organometallic Compounds / administration & dosage
  • Organometallic Compounds / blood
  • Organometallic Compounds / pharmacokinetics*
  • Organometallic Compounds / urine

Substances

  • Organometallic Compounds
  • Meglumine
  • Meglumine Antimoniate
  • Antimony